Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Italfarmaco clinical trials
The registry lists 51 studies whose lead sponsor is Italfarmaco or one of 3 companies grouped under it. 11 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 29, 2026.
Keep track of what changes. Save the Italfarmaco studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Italfarmaco.
- Italfarmaco35 studiesSame company
Something wrong?
- Lacer S.A.13 studies →Acquired
Something wrong?
- 1 study →
- Italfarmaco S.A1 studySame company
Something wrong?
- ITF Therapeutics LLC1 study →Subsidiary
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 50 of 51. Browse all 51 →
- Effect of the Dietary Supplement to Alleviate Dry Mouth.Not yet recruitingNCT07847840Not applicable
Sponsor listed in the registry: Lacer S.A. · Lacer S.A. — acquired company within the Italfarmaco group
- Evaluation of the Mouthwash Effect on Maintaining Healthy Microbiome in Healthy Mouth.Not yet recruitingNCT07844993Not applicable
Sponsor listed in the registry: Lacer S.A. · Lacer S.A. — acquired company within the Italfarmaco group
- Evaluation of the Dietary Supplement Effect on Improvement of Hair Condition in Subjects With Occasional Hair Loss.Not yet recruitingNCT07835646Not applicable
Sponsor listed in the registry: Lacer S.A. · Lacer S.A. — acquired company within the Italfarmaco group
- Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular DystrophyRecruitingNCT05933057Phase 3
- Evaluation of the Effect of Combined Use of Cosmetic Products for Dry and Itchy Skin.Not yet recruitingNCT07695805Not applicable
Sponsor listed in the registry: Lacer S.A. · Lacer S.A. — acquired company within the Italfarmaco group
- A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular DystrophyRecruitingNCT07127978
Sponsor listed in the registry: ITF Therapeutics LLC
- Evaluation of the Effect of the Toothpaste on Delicate GumsRecruitingNCT07494747Not applicable
Sponsor listed in the registry: Lacer S.A. · Lacer S.A. — acquired company within the Italfarmaco group
- Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia VeraRecruitingNCT06093672Phase 3
- Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability StudyRecruitingNCT03373968Phase 2/3
- Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years OldRecruitingNCT06769633Phase 2
- A Multicentre, Prospective, Open-label, Non-comparative StudyRecruitingNCT06067256Phase 4
- Evaluation of the Whitening Effect in Subjects After Professional Tooth Cleaning ProcedureCompletedNCT07438990Not applicable
Sponsor listed in the registry: Lacer S.A. · Lacer S.A. — acquired company within the Italfarmaco group
- Evaluation of the Effect of the Mouthwash on Delicate GumsCompletedNCT07551908Not applicable
Sponsor listed in the registry: Lacer S.A. · Lacer S.A. — acquired company within the Italfarmaco group
- Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic FunctionCompletedNCT06736223Phase 1
- Evaluation of Toothpaste Effect in Volunteers With Dental SensitivityCompletedNCT07593755Not applicable
Sponsor listed in the registry: Lacer S.A. · Lacer S.A. — acquired company within the Italfarmaco group
- Evaluation of the Effect of the Gel on Sensitive TeethCompletedNCT07596797Not applicable
Sponsor listed in the registry: Lacer S.A. · Lacer S.A. — acquired company within the Italfarmaco group
- Clinical Study to Evaluate Effect of Shampoo in Subjects With Hair Loss.CompletedNCT07433933
Sponsor listed in the registry: Lacer S.A. · Lacer S.A. — acquired company within the Italfarmaco group
- Evaluation of Hydrating Cream Effect on Subjects With Dry Skin.CompletedNCT07393191Not applicable
Sponsor listed in the registry: Lacer S.A. · Lacer S.A. — acquired company within the Italfarmaco group
- Evaluation of Mouthwash Use in Hygiene and Recovery After Interventions in GumsCompletedNCT07385586Not applicable
Sponsor listed in the registry: Lacer S.A. · Lacer S.A. — acquired company within the Italfarmaco group
- Multicenter Prospective Real-world Observational Study to Evaluate the Effectiveness of Phlebotonics, as Conservative Therapy in a Cohort of Patients With Symptomatic Hemorrhoidal Disease (HD) of I, II or III Goligher GradeCompletedNCT07376928
- Evaluation of the Dietary Supplement Efficacy Against Hair Loss in Subjects Suffering From Hair LossCompletedNCT07358403Not applicable
Sponsor listed in the registry: Lacer S.A. · Lacer S.A. — acquired company within the Italfarmaco group
- Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative NeoplasmsActive, not recruitingNCT01761968Phase 2
- Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)CompletedNCT05860114Phase 1
- Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp ActivityCompletedNCT05492318Phase 1
- Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular DystrophyCompletedNCT03238235Phase 2
- The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)CompletedNCT05845567Phase 1
- Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC IntervalCompletedNCT04821063Phase 1
- A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMDCompletedNCT01761292Phase 1/2
- Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's DiseaseTerminatedNCT00792740Phase 1/2
- Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular DystrophyCompletedNCT02851797Phase 3
- Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00792506Phase 2
- phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma PatientsTerminatedNCT00496431Phase 1/2
- Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic LeukemiaTerminatedNCT00792831Phase 2
- Open Non-Comparative Study To Evaluate Administration Of a New NutraceuticalCompletedNCT04245761Not applicable
- Prevalence And Burden Of Nausea And Vomiting In Pregnant WomenStatus unknownNCT04926727
- Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's LymphomaCompletedNCT00792467Phase 1/2
- Post Marketing Follow Up Study To Evaluate Performance Safety Quality of Menopausal Transition Women Treated With AinaraCompletedNCT04362371Not applicable
- Open Non-Comparative Clinical Trial Study To Evaluate The Performance And Safety Of Ainara®CompletedNCT04245358Not applicable
- Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic ArthritisCompletedNCT00570661Phase 2
- Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic ArthritisTerminatedNCT01557452Not applicable
- Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy.CompletedNCT04574999Phase 3
Sponsor listed in the registry: Italfarmaco S.A
- Clinical Trial Study To Evaluate The Performance And Safety Of Ainara®CompletedNCT04245293Not applicable
- Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative DiseasesCompletedNCT00606307Phase 2
- Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia VeraCompletedNCT00928707Phase 2
- A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia VeraCompletedNCT01901432Phase 1/2
- Phase II Study With ITF2984 in Acromegalic PatientsCompletedNCT02111044Phase 2
- Efficacy and Safety Dose Finding Study of Givinostat to Treat Polyarticular Course Juvenile Idiopathic ArthritisTerminatedNCT01261624Phase 2
- A Two Part Phase 1, Repeated Doses and Continuous Infusion Study With ITF2984 in Healthy VolunteersCompletedNCT01897844Phase 1
- Interest of Intravaginal Electro-stimulation at Home by GYNEFFIK® Compared to Usual Care in Incontinent Patients With Prior Perineal ReeducationStatus unknownNCT02029027Phase 4
Sponsor listed in the registry: Effik · First submitted before Effik became part of Italfarmaco
- ITF2984 Repeated Doses Study in Healthy VolunteersCompletedNCT01871844Phase 1